Net loss for the three months ended March 31, 2026, widened to $52.8 million, compared to $37.0 million for the same period in 2025. Research and development expenses increased by 11% to $33.1 million in Q1 2026, primarily due to higher employee-related and consulting expenses, and manufacturing costs. Selling, general and administrative expenses surged by 174% to $17.4 million in Q1 2026, driven by commercial headcount additions and launch-related activities for gedatolisib. As of March 31, 2026, the company had $387.1 million in cash, cash equivalents, and short-term investments, with an accumulated deficit of $501.7 million. The FDA accepted the New Drug Application (NDA) for gedatolisib in HR+/HER2PIK3CA WT advanced or metastatic breast cancer (ABC), granting Priority Review with a PDUFA goal date of July 17, 2026. Positive topline results were announced on May 1, 2026, for the VIKTORIA-1 Phase 3 clinical trial's PIK3CA MT cohort, demonstrating statistically significant and clinically meaningful improvement in progression-free survival (PFS). The VIKTORIA-2 Phase 3 clinical trial's design was amended to include endocrine-sensitive patients and remove ribociclib as a treatment partner in one arm, with topline data expected by the end of 2028 for Study 1 and in 2030 for Study 2. An ongoing Phase 1b/2 clinical trial (CELC-G-201) for gedatolisib in metastatic castration-resistant prostate cancer (mCRPC) showed a 6-month radiographic PFS rate of 67% and median rPFS of 9.1 months for combined arms. A patent application was submitted to the USPTO for a subcutaneous formulation of gedatolisib, aiming to provide an alternative to intravenous administration.